ELAN INVESTOR ALERT: Elanco is being Investigated for Securities Fraud by BFA Law; Investors that Suffered Losses are Notified to Contact the Firm (NYSE:ELAN)

Why Did Elanco's Stock Drop? With respect to these treatments, the company stated that the FDA "has all data necessary to complete its review. All technical sections, including the label, are expected to be approved before the end of June [2024]." However, on June 27, 2024, Elanco announced that it expected the FDA would not approve either drug in June 2024 and that Zenrelia would come with a boxed warning on safety. As a result of the news, Elanco's stock price declined over 21%, from $17.97 per share on J ...